Management report >
Results of operations, financial position, assets and liabilities >
Results of operations >
Reconciliation to group net income
- Sales
- Earnings structure
- Reconciliation to group net income
- Development of other major items in the statement of income
- Value added
Reconciliation to group net income
Reconciliation
| 2010 | 2009 | |||
|---|---|---|---|---|
| € in millions | Other financial result | Net income | Other financial result | Net income |
| 1 Net income attributable to Fresenius SE & Co. KGaA adjusted for the special items relating to the acquisition of APP Pharmaceuticals. 2 The special items are included in the column "Corporate/Other" in the segment reporting. 3 Net income attributable to Fresenius SE & Co. KGaA |
||||
| Net income1 | 660 | 514 | ||
| Other financial result:2 | ||||
| Mandatory Exchangeable Bonds (MEB) (mark-to-market accounting) | -98 | -70 | -37 | -26 |
| Contingent Value Rights (CVR) (mark-to-market accounting) | 32 | 32 | 6 | 6 |
| Earnings according to U.S. GAAP3 | -66 | 622 | -31 | 494 |
The table above shows the special items relating to the acquisition of APP Pharmaceuticals in the reconciliation from net income1 to earnings according to U.S. GAAP.
The Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR) are recognized as liabilities. The repayment value of the CVR and the derivative elements of the MEB are measured at market prices. The change in value (mark-to-market accounting) results either in a gain or an expense until the end of maturity.
Since Adjusted EBITDA for the CVR measuring period did not exceed the threshold amount, no amounts will be payable on the CVRs and the CVRs will expire valueless.
Back to:
Earnings structure
Earnings structure
Continue reading:
Development of other major items in the statement of income
Development of other major items in the statement of income